Vaccine Adverse Reaction Clinical Trial
Official title:
Dose-response Study a Glucoside- and Rutinoside-rich Crude Material in Relieving Side Effects of COVID-19 Vaccines
Urgent vaccine development plus the characteristics of the coronavirus have caused the relatively more safety problems in COVID-19 vaccines than other classic vaccines and unavoidably raises more concerns among those who accept or consider to be vaccinated. Mulberry juice consists of a large amount of anthocyanin. The abnormally high interleukin-17A level is frequently seen in patients with inflammation status or diseases with inflammation features. Some specific anthocyanins can reduce cyclooxygenase and nitrogen oxide, and the pharmacological effect of the major anthocyanin in mulberry juice imitates that of interleukin-17A antagonists. These features make mulberry juice a potential crude material for reducing inflammation and pain induced by COVID-19 vaccinations. The investigators propose a randomized control trial to explore the dose-response effects of three different volumes of mulberry juice on the incidence and severity of COVID-19 induced side effects. The findings should be helpful for nutrition supplementation in COVID-19 vaccinations and may improve public coordination of COVID-19 vaccinations.
Since the outbreak of Coronavirus Disease-2019 (COVID-19), the size of the infected population continues to expand, and the number of deaths due to the infection continues to climb. Massive vaccination has become the most critical measure to control the pandemic. Vaccination may cause side effects. Urgent vaccine development plus the characteristics of the coronavirus have caused the relatively more safety problems in COVID-19 vaccines than other classic vaccines and unavoidably raises more concerns among those who accept or consider to be vaccinated. Mulberry juice consists of a large amount of anthocyanin. The abnormally high interleukin-17A level is frequently seen in patients with inflammation status or diseases with inflammation features. Previous cell and animal studies have shown that some specific anthocyanins can reduce cyclooxygenase and nitrogen oxide, and the pharmacological effect of the major anthocyanin in mulberry juice imitates that of interleukin-17A antagonists. These features make mulberry juice a potential crude material for reducing inflammation and pain induced by COVID-19 vaccinations. The investigators propose a randomized control trial investigating the dose-response effects of three different volumes of mulberry juice on the incidence and severity of COVID-19 induced side effects and build up initial dose-response models for future reference in nutrition supplementation in COVID-19 vaccinations and improve public coordination of COVID-19 vaccinations. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03966391 -
Effectiveness of CARD for Improving School-Based Immunizations
|
N/A | |
| Completed |
NCT04530357 -
Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine
|
Phase 1/Phase 2 | |
| Terminated |
NCT03966300 -
Improving the School Vaccination Experience: What CARDs Are You Going to Play?
|
N/A | |
| Active, not recruiting |
NCT06286488 -
Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza
|
Phase 4 | |
| Recruiting |
NCT05546502 -
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children
|
Phase 3 | |
| Active, not recruiting |
NCT05483725 -
Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
|
||
| Completed |
NCT03600428 -
Safety of LAIV4 in Children With Asthma
|
Phase 4 | |
| Completed |
NCT03400878 -
Comparing Morbidity and Mortality Effects of Two Different Strains of BCG
|
Phase 4 | |
| Completed |
NCT05116748 -
COVID19 Vaccine in SOT Adult Recipients
|
||
| Not yet recruiting |
NCT05171946 -
Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults
|
Phase 1 | |
| Recruiting |
NCT05128721 -
Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)
|
Phase 1 | |
| Withdrawn |
NCT04894682 -
Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor
|
||
| Active, not recruiting |
NCT04801667 -
Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients
|
Phase 4 | |
| Not yet recruiting |
NCT05283902 -
Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
|
||
| Recruiting |
NCT05095844 -
National Vaccine Adverse Event Reporting Survey and Etiology
|
||
| Recruiting |
NCT05315856 -
Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms
|
||
| Recruiting |
NCT05898464 -
Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV
|
Phase 4 | |
| Recruiting |
NCT05212792 -
Genomics and COVID-19 Vaccine Adverse Events
|
||
| Recruiting |
NCT05258708 -
COVID-19 Vaccine Reactogenicity and Immunogenicity
|
||
| Not yet recruiting |
NCT05482295 -
Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)
|
Phase 3 |